JP6046060B2 - エイズの治療のための、ポリアニオン性ポリペプチドと結合しているｃｄ４受容体由来ペプチドを含んでなる新規コンジュゲート分子 - Google Patents

エイズの治療のための、ポリアニオン性ポリペプチドと結合しているｃｄ４受容体由来ペプチドを含んでなる新規コンジュゲート分子 Download PDF

Info

Publication number
JP6046060B2
JP6046060B2 JP2013558459A JP2013558459A JP6046060B2 JP 6046060 B2 JP6046060 B2 JP 6046060B2 JP 2013558459 A JP2013558459 A JP 2013558459A JP 2013558459 A JP2013558459 A JP 2013558459A JP 6046060 B2 JP6046060 B2 JP 6046060B2
Authority
JP
Japan
Prior art keywords
group
peptide
seq
asu
conjugate molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013558459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509604A (ja
JP2014509604A5 (enExample
Inventor
フランソワーズ、バルー
ユーグ、ロルタ−ヤコブ
ダビド、ボナフェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of JP2014509604A publication Critical patent/JP2014509604A/ja
Publication of JP2014509604A5 publication Critical patent/JP2014509604A5/ja
Application granted granted Critical
Publication of JP6046060B2 publication Critical patent/JP6046060B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2013558459A 2011-03-18 2012-03-16 エイズの治療のための、ポリアニオン性ポリペプチドと結合しているｃｄ４受容体由来ペプチドを含んでなる新規コンジュゲート分子 Expired - Fee Related JP6046060B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305309.4 2011-03-18
EP11305309A EP2505210A1 (en) 2011-03-18 2011-03-18 Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanionic polypeptide for the treatment of aids
US201261590992P 2012-01-26 2012-01-26
US61/590,992 2012-01-26
PCT/EP2012/054674 WO2012126833A1 (en) 2011-03-18 2012-03-16 New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids

Publications (3)

Publication Number Publication Date
JP2014509604A JP2014509604A (ja) 2014-04-21
JP2014509604A5 JP2014509604A5 (enExample) 2015-04-30
JP6046060B2 true JP6046060B2 (ja) 2016-12-14

Family

ID=44118425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013558459A Expired - Fee Related JP6046060B2 (ja) 2011-03-18 2012-03-16 エイズの治療のための、ポリアニオン性ポリペプチドと結合しているｃｄ４受容体由来ペプチドを含んでなる新規コンジュゲート分子

Country Status (9)

Country Link
US (1) US9078928B2 (enExample)
EP (2) EP2505210A1 (enExample)
JP (1) JP6046060B2 (enExample)
CN (1) CN103429269B (enExample)
BR (1) BR112013023859A2 (enExample)
CA (1) CA2830012C (enExample)
MX (1) MX336727B (enExample)
WO (1) WO2012126833A1 (enExample)
ZA (1) ZA201306956B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016062854A1 (en) * 2014-10-24 2016-04-28 Institut Pasteur Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to an anionic polypeptide for the treatment of aids
WO2017184564A1 (en) * 2016-04-18 2017-10-26 Icagen, Inc. Sensors and sensor arrays for detection of analytes
US11014961B2 (en) 2017-01-25 2021-05-25 Massachusetts Institute Of Technology Self-labeling miniproteins and conjugates comprising them
CN109081789B (zh) * 2017-06-13 2021-01-01 首都医科大学 氨基正己酰氨基甲环酰氨基正己酰脂肪氨基酸，其合成，活性和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002338600A (ja) * 2001-05-17 2002-11-27 Japan Science & Technology Corp Ｈｉｖ−１の感染を抑制するポリペプチド
RU2270690C1 (ru) * 2004-06-11 2006-02-27 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") Комплексное анти-вич соединение
FR2904627B1 (fr) * 2006-08-04 2008-11-07 Pasteur Institut Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation
EP2087911A1 (en) * 2008-02-06 2009-08-12 Institut Pasteur Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS

Also Published As

Publication number Publication date
JP2014509604A (ja) 2014-04-21
WO2012126833A1 (en) 2012-09-27
EP2686019B1 (en) 2017-03-01
MX2013010688A (es) 2014-03-27
MX336727B (es) 2016-01-27
EP2505210A1 (en) 2012-10-03
US9078928B2 (en) 2015-07-14
CN103429269B (zh) 2016-05-11
CA2830012C (en) 2018-11-06
EP2686019A1 (en) 2014-01-22
US20140107043A1 (en) 2014-04-17
CA2830012A1 (en) 2012-09-27
ZA201306956B (en) 2014-05-28
BR112013023859A2 (pt) 2018-09-25
CN103429269A (zh) 2013-12-04

Similar Documents

Publication Publication Date Title
JP6046060B2 (ja) エイズの治療のための、ポリアニオン性ポリペプチドと結合しているｃｄ４受容体由来ペプチドを含んでなる新規コンジュゲート分子
CA3210657A1 (en) Glucagon-like peptide-1 receptor antagonists
JP7733664B2 (ja) Ｅｐｉ－ｘ４系ペプチドおよびその誘導体
US5767072A (en) Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
JP6656661B2 (ja) プレキシンの結合調節剤
Wan et al. Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages
US20240366775A1 (en) Human transferrin receptor binding antibody-peptide conjugate
JP6647207B2 (ja) ヘマグルチニン結合ペプチド
ES2526060T3 (es) Péptido y tratamiento para la infección del VIH-1
EP3220957B1 (en) Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to an anionic polypeptide for the treatment of aids
US20240189390A1 (en) Treatment of cerebrovascular events and neurological disorders
US10738083B2 (en) Influenza virus neutralizing peptidomimetic compounds
JP2025525217A (ja) グルカゴン様ペプチド－１受容体アンタゴニスト
RU2816717C2 (ru) Композиции и способы для лечения вирусных инфекций
WO2025167910A1 (zh) 一种可口服的长效多肽类hiv灭活剂
CA2065029A1 (en) Therapeutic compositions; methods for treatment of hiv infections
JP2025186263A (ja) Ｅｐｉ－ｘ４系ペプチドおよびその誘導体
JPH05331195A (ja) 新規なペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161116

R150 Certificate of patent or registration of utility model

Ref document number: 6046060

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees